PALI 2108
Alternative Names: GT-2108; PALI-2108Latest Information Update: 19 Sep 2025
At a glance
- Originator Giiant Pharma
- Developer Giiant Pharma; Palisade Bio
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ulcerative colitis
- Preclinical Crohn's disease; Inflammatory bowel diseases
Most Recent Events
- 17 Sep 2025 Updated efficacy, pharmacokinetics and adverse events data from a phase I trial in Ulcerative colitis released by Palisade Bio
- 08 Sep 2025 Palisade Bio received IND clearance from health Canada for the initiation of phase Ib trial in Fibrostenotic Crohn’s Disease
- 08 Sep 2025 Palisade Bio plans to initiate a phase Ib trial for Fibrostenotic Crohn’s Disease